Biotech IPOS, China Risk, FDA Shifts

Kilder

• BioPharma Dive: Latigo IPO raises nearly $350M for pain drug development
• Endpoints: BINSA legislation to limit biotech deals in China unveiled in Senate
• STAT: Is the biotech capital of the world moving?
• Endpoints: BioMarin discontinues rare disease drug; CSL and Arcturus split up
• Allsci: BioMarin drops BMN 401 following unsuccessful pivotal trial - AllSci
• Endpoints: China biotech will slow as it nears R&D frontier, Pfizer’s Baum predicts
• STAT: Is the biotech capital of the world moving?

Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.